ArticleCancers2023

Longitudinal Study of Advanced Non-Small Cell Lung Cancer with Initial Durable Clinical Benefit to Immunotherapy: Strategies for Anti-PD-1/PD-L1 Continuation beyond Progression.

Ivan Pourmir et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.